• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[强心苷的过去与现在。III. 药代动力学]

[The past and the present of cardiac glycosides. III. Pharmacokinetics].

作者信息

Synek P

机构信息

Institutu pro dalsí vzdĕlávání lékarů a farmaceutů, Praha.

出版信息

Cas Lek Cesk. 1991 Feb 1;130(5):148-51.

PMID:2004406
Abstract

The molecular structure is one of the keypoints that govern both the extent of extracardiac action of cardiac glycosides and their different kinetics. The apolar, fat soluble digitoxin is very well absorbed from the intestine, its onset of action is slow, binds to a high degree to albumin and undergoes enterohepatic recirculation which accounts for a long elimination half time and stability of plasmatic levels. Digitoxin is largely excreted via gastrointestinal tract. The absorption of digoxin is less reliable, onset of action occurs earlier and the binding to albumin is considerably less than that of digitoxin. The drawback, however small, of digoxin lies in a lower stability of plasma levels and prevailing renal excretion. The molecule of strophatin is highly polar, its absorption from the intestine negligible and can be administered only intravenously. The onset of action is prompt, elimination half time short and about half the injected amount is excreted extrarenally.

摘要

分子结构是决定强心苷心脏外作用程度及其不同动力学的关键因素之一。非极性、脂溶性的洋地黄毒苷从肠道吸收良好,起效缓慢,与白蛋白高度结合,并经历肠肝循环,这导致其消除半衰期长且血浆水平稳定。洋地黄毒苷主要通过胃肠道排泄。地高辛的吸收不太可靠,起效较早,与白蛋白的结合远低于洋地黄毒苷。然而,地高辛的缺点在于血浆水平稳定性较低且主要经肾脏排泄,尽管这个缺点很小。毒毛花苷分子极性很强,从肠道吸收可忽略不计,只能静脉给药。起效迅速,消除半衰期短,约一半的注射量经肾外排泄。

相似文献

1
[The past and the present of cardiac glycosides. III. Pharmacokinetics].[强心苷的过去与现在。III. 药代动力学]
Cas Lek Cesk. 1991 Feb 1;130(5):148-51.
2
Current status of cardiac glycoside drug interactions.强心苷类药物相互作用的现状
Clin Pharm. 1985 Jul-Aug;4(4):404-13.
3
Digitalis pharmacokinetics and therapy with respect to impaired renal function.关于肾功能受损的洋地黄药代动力学及治疗
Klin Wochenschr. 1977 Jan 1;55(1):1-11. doi: 10.1007/BF01469777.
4
Disease-related alterations in cardiac glycoside disposition.心脏苷类药物处置的疾病相关改变。
Clin Pharmacokinet. 1982 Sep-Oct;7(5):434-51. doi: 10.2165/00003088-198207050-00004.
5
[Pharmacokinetics of cardiac glycosides and clinical consequences].[强心苷类药物的药代动力学及临床后果]
Fortschr Med. 1977 Apr 14;95(14):909-15, 951-4.
6
Digitalis therapy in renal failure with special regard to digitoxin.肾衰竭中的洋地黄疗法,特别关注地高辛。
Int J Clin Pharmacol Ther Toxicol. 1981 Apr;19(4):175-84.
7
[Renal elimination kinetics of various several cardiac glycosides].[多种强心苷的肾脏排泄动力学]
Dtsch Med Wochenschr. 1972 Oct 6;97(40):1485-90. doi: 10.1055/s-0028-1107587.
8
[Modern cardiac glycoside therapy].[现代强心苷治疗]
Wien Med Wochenschr. 1978;128(22):689-96.
9
Interruption of the enterohepatic circulation of digitoxin by cholestyramine. I. Protection against lethal digitoxin intoxication.考来烯胺对洋地黄毒苷肝肠循环的阻断作用。I. 对致死性洋地黄毒苷中毒的保护作用。
J Clin Invest. 1971 Dec;50(12):2626-37. doi: 10.1172/JCI106763.
10
Pharmacokinetics, bioavailability and serum levels of cardiac glycosides.强心苷的药代动力学、生物利用度及血清水平
J Am Coll Cardiol. 1985 May;5(5 Suppl A):43A-50A. doi: 10.1016/s0735-1097(85)80462-9.